Kornimate/medical-research-clean huggingface dataset:
measuring the plasma clearance of iohexol to estimate glomerular filtration rate in intensive care unit patients: preliminary feasibility study

Conditions: Acute Circulatory Failure

Summary: the objective of this study is to assess the feasibility of estimating the clearance of iohexol as an indirect measure of glomerular filtration rate in patients with unstable renal function in the intensive care unit through analysis of rich iohexol plasma kinetics.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years * patient admitted to intensive care for less than 12 hours * acute circulatory failure * patient carrying an arterial catheter * informed consent obtained * affiliated to social security system exclusion criteria: * administration of iohexol the week before intensive care admission * administration of iohexol expected within 24 hours of study entry * known history of cutaneous immediate or delayed allergic reaction to the injection of the product * indication for albumin transfusion within 24 hours of potential inclusion in the study * pregnancy or breastfeeding in progress * patient under guardianship or judicial protection known at the time of inclusion * withdrawal of consent * administration of iohexol outside the study within 24 hours after administration of iohexol in the context of the study * administration of intravenous albumin in the 24 hours following administration of iohexol in the context of the study
the relationship between triceps skinfold and overall survival of pancreas, bile duct, gallbladder cancer

Conditions: Pancreas Cancer; Cholangiocarcinoma; Gallbladder Cancer

Summary: in this study, the investigators aim to demonstration of relationship between triceps skinfold thickness and overall survival of pancreatic cancer, cholangiocarcinoma and gb cancer.

cachexia is frequently seen in pancreatic cancer(70-80%) and associated with reduced survival, reduced treatment tolerance and reduction in qol. in recent studies, low-normal bmi have worse outcome (overall mortality) in cardiovascular, malignant, chronic disease (so called "obesity paradox") bmi is simple method but hard to define body composition because bmi is based on only weight and height. skinfold thickness is strongly associated with body fatness than bmi. in this study, the ivestigators aim to demonstration of relationship between triceps skinfold thickness and overall survival of pancreatic cancer, cholangiocarcinoma and gb cancer.

Eligibility criteria:
inclusion criteria: * newly diagnosed pancreatic, bile duct or gallbladder cancer patients, undergoing therapeutic management (including surgery, chemotherapy or palliative care). * age above 18 years old exclusion criteria: * other malignant disease * underlying intestinal disease that cause absorprtion disorder * underlying psychiatric disorder such as eating disorder (bulimia, anorexia)
shr-1701 in combination with chemotherapy and radiotherapy in locally advanced rectal cancer

Conditions: Locally Advanced Rectal Cancer

Summary: this study will evaluate the efficacy and safety of shr-1701 combined with radiotherapy and chemotherapy as perioperative treatment for locally advanced rectal cancer. eligible patients will receive standard chemoradiation with shr-1701 followed by xelox combined with shr-1701. in all subjects, restaging pelvic mri with chest and abdominal ct will be performed after completion of neoadjuvant treatment to determine resectability and to rule out any evidence of metastases. subjects who have resectable disease will undergo surgery. adjuvant xelox combined with shr-1701 will be given after surgery.


Eligibility criteria:
inclusion criteria: 1. be willing and able to provide written informed consent for the trial. 2. locally advanced rectal adenocarcinoma and was evaluated as resectable ; 3. the inferior margin of the tumor ≤ 10 cm from the anal verge ; 4. no prior anti-cancer treatment for rectal cancer; 5. estern cooperative oncology group (ecog) performance status (ps) of 0 or 1; 6. adequate hematologic and end-organ function; 7. contraception was initiated from the signing of the informed consent until at least 6 months after the last dosing of the study drug exclusion criteria: 1. unresectable disease determined by investigators 2. recurrent rectal cancer 3. evidence of metastatic disease or lateral lymph node metastases 4. presence of synchronous colorectal cancer 5. presence of obstruction or imminent obstruction 6. not eligible for long-course radiotherapy 7. severe cardiovascular and cerebrovascular diseases;have clinical heart symptoms or diseases that are not well controlled 8. prior malignancy within the prior 5 years. exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical/breast cancer.
genetic characterization of cardiomyopathies (policardiomio2021)

Conditions: Cardiomyopathies

Summary: cardiomyopathy refers to a diverse group of myocardial diseases with multiple causes. in 1995, the world health organization classified cardiomyopathies into hypertrophic, dilated, restrictive, and mixed type. this classification is based on the pathophysiology of the disease. however, with rapid evolution of molecular genetics in cardiology, the american heart association in 2006 has classified cardiomyopathies into two major groups based on predominant organ involvement and etiology; primary cardiomyopathies are those solely or predominantly confined to heart muscle and are relatively few in number. secondary cardiomyopathies show pathologic myocardial involvement as part of a large number and variety of generalized systemic (multiorgan) disorders.current evidence supports the use of genetic testing in clinical practice to improve risk stratification for clinically affected patients and their at-risk relatives for cardiomyopathies.


Eligibility criteria:
inclusion criteria: * presence of structural cardiomyopathy * first degree relatives for cardiomyopathy exclusion criteria: * age \> 80 * presence of sufficient conditions to explain the clinical condition of cardiomyopathy * peripartum cardiomyopathy

Keywords: cardiomyopathy hypertrophic dilated arvd restrictive ngs gene mutation
common engagement strategies (common factors) for childhood anxiety

Conditions: Anxiety

Summary: this trial examines the effectiveness of training pediatric primary care providers (nurse practitioners, doctors) to use of strategies that enhance family/youth empowerment and engagement during office visits for children with mild to moderate problems with anxiety. children coming for routine care at one clinic are screened for anxiety symptoms and seen by either a specially trained provider or one of the clinic's other regular staff members.

children who are thought to have mild to moderate anxiety will, via their parents, be offered the opportunity to receive treatment from their pediatric primary care provider. providers will either use their existing anxiety approaches or will use those approaches combined with extra communication skills designed to promote patient and parent engagement in care. children will be seen for up to 4 30-minute visits at 2 week intervals, with a follow-up telephone call 3 months later to asses the impact of treatment. children with more severe anxiety (or those whose parents so desire) will be referred for specialized mental health care.

Eligibility criteria:
inclusion criteria: * coming for well-child visit to designated clinical site; * scared score 25 or greater exclusion criteria: * acute medical illness, scared 40 or greater
chiropractic distraction spinal manipulation- lumbar stenosis study

Conditions: Spinal Stenosis Lumbar

Summary: to assess the effect of chiropractic distraction manipulation on postural sway and simple measures of performance in patients with the clinical diagnosis of lumbar spinal stenosis.

this study aims to assess the effect of chiropractic distraction manipulation in reducing postural sway and improving performance-based mobility and disability in patients with the clinical diagnosis of lumbar spinal stenosis. this study will identify if distraction spinal manipulation will reduce postural sway center of pressure (cop) movements as determined by a force plate, if distraction spinal manipulation will improve simple measures of performance-based mobility and if distraction spinal manipulation will improve perception of balance confidence and will reduce self-rated stenosis associated disability.

Eligibility criteria:
inclusion criteria: * age greater than 48 years old * patient has leg or buttock pain while walking * patient feels relief of symptoms with bending (flexing) forward * patient feels relief when using a shopping cart of bicycle * patient has motor or sensory disturbance while walking * patient has normal and symmetrical foot pulses * patient has lower extremity weakness * patient has low back pain * duration of symptoms and signs for more than 1 month * able to stand and walk without assistive devices for at least 20 minutes * able to give written informed consent and complete interviews and questionnaires in english exclusion criteria: * complicated spinal pain due to fracture, tumor, infection, or severe spondyloarthropathy * has other severe co-morbidities, including progressive neurological deficit * other serious pathologies of the locomotor system * no correspondence availability through email * inability to read/ comprehend english * compensation or seeking compensation from a third-party liability or workers' compensation * previous spinal manipulation within the past month

Keywords: chiropractic manipulation postural sway distraction manipulation performance-based mobility
clinical investigation of the visual outcomes and safety of a trifocal toric iol in an asian population

Conditions: Aphakia; Corneal Astigmatism

Summary: the purpose of this study is to evaluate the clinical performance of the acrysof® iq panoptix® toric trifocal intraocular lens (iol) when implanted in the eye following cataract removal in an asian population.

both eyes will be implanted with the panoptix toric trifocal iol. the eye with the highest astigmatism will be implanted first. the second eye will be implanted within 7-14 days of the first eye. subjects will attend a total of 10 scheduled visits as follows: 1 screening visit, 1 operative visit for each eye, 2 post-operative visits for each eye, and 3 postoperative visits where both eyes will be evaluated. the duration of participation for each subject will be approximately 8 months. this study will be conducted in australia.

Eligibility criteria:
key inclusion criteria: * planned bilateral cataract removal followed by posterior chamber iol implantation with panoptix toric (tfnt30, tfnt40, tfnt50, or tfnt60); * calculated target residual refractive error within ±0.50 diopter (d) of emmetropia within the commercially available iol power range in both operative eyes; * preoperative regular corneal keratometric astigmatism with predicted residual refractive astigmatism ≤ 0.50 diopter (d) in both operative eyes; * other protocol-defined inclusion criteria may apply. key exclusion criteria: * preoperative irregular astigmatism; * clinically significant corneal abnormalities; * glaucoma; * history of or current retinal disease; anterior or posterior segment inflammation; * other planned ocular surgical procedures including, but not limited to, limbal relaxing incision (lri)/astigmatic keratotomy and laser-assisted in situ keratomileusis (lasik); * other protocol-defined exclusion criteria may apply.

Keywords: intraocular lens cataract
efficacy/safety study to explore a new revised topical formulation in atopic dermatitis

Conditions: Dermatitis, Atopic

Summary: the study shall explore whether treatment of atopic dermatitis is equally effective with respect to a marketed medical device and a new medical device.


Eligibility criteria:
inclusion criteria: * male or female caucasians aged between 18 and 60 years * patients with mild to moderate ad (atopic dermatitis) presenting a scoring ad (scorad) rating below 50 * skin type i - iv according to fitzpatrick * acute ad symptoms on each assessment areas (local scorad ≥ 3 and \</= 12) at baseline * acute symptom of pruritus at baseline exclusion criteria: * any other skin disease at the test area that would interfere the clinical assessment in the opinion of the investigator * moles, tattoos, strong pigmentation, or scars at the test area that would interfere the clinical assessment * regular intake of antiphlogistic drugs (for example, nonsteroidal anti-inflammatory drug \[nsaids\]) * any condition or treatment which might influence the trial (e.g. any treatment with topical antibiotics, antifungals, or corticoids) within 14 days prior to screening as well as during the trial (exception: topical treatment of ad lesions other than the test areas (for example, face) with low potency steroids restricted to small areas) * uv-therapy or the use of solarium within 30 days before screening as well as during the trial * any alternative treatment of ad (e.g. acupuncture, kinesiology, and homoeopathy) within 30 days before screening as well as during the trial

Keywords: phoenix mild atopic dermatitis efficacy safety
robotic-assisted and laparoscopic right colectomy study - intracorporeal vs. extracorporeal anastomoses

Conditions: Benign Right Colon Disease; Malignant Right Colon Disease

Summary: to compare intracorporeal and extracorporeal anastomoses for robotic-assisted and laparoscopic right colectomies

this is a prospective multicenter observational study to evaluate outcomes of intracorporeal and extracorporeal anastomoses for robotic-assisted and laparoscopic right colectomies.

Eligibility criteria:
inclusion criteria: * subject is 18 years or older * subject undergoing either laparoscopic or robotic-assisted right colectomy for benign or malignant right colon disease * subject undergoing intracorporeal or extracorporeal anastomosis proximal to mid-transverse colon exclusion criteria: * subject is contraindicated for general anesthesia or surgery * emergent case * subject has perforated, obstructing or locally invasive neoplasm (t4b) * subject with inflammatory bowel disease * subject with prior incisional hernia repair * planned right colectomy along with major concomitant procedures (e.g. hepatectomies, other intestinal resections). * metastatic disease with life expectancy of less than 1 year * pregnant or suspect pregnancy * subject is mentally handicapped or has a psychological disorder or severe systemic illness that would preclude compliance with study requirements or ability to provide informed consent * subject belonging to other vulnerable population, e.g, prisoner or ward of the state
safety and tolerability study of pci-32765 in b cell lymphoma and chronic lymphocytic leukemia

Conditions: B-cell Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Diffuse Well-differentiated Lymphocytic Lymphoma; B Cell Lymphoma; Follicular Lymphoma; Mantle Cell Lymphoma; Non-Hodgkin's Lymphoma; Waldenstrom Macroglobulinemia; Burkitt Lymphoma; B-Cell Diffuse Lymphoma

Summary: the purpose of this study is to determine the long-term safety of a fixed-dose, daily regimen of pci-32765 po in subjects with b cell lymphoma or chronic lymphocytic leukemia/small lymphocytic leukemia (cll/sll).


Eligibility criteria:
inclusion criteria: * men and women with recurrent surface immunoglobulin positive b cell non-hodgkin's lymphoma (nhl) according to who classification (including, but not limited to, cll/sll, waldenström's macroglobulinemia \[wm\], mantle cell lymphoma \[mcl\], and diffuse large b cell lymphoma \[dlbcl) who have met requirements for roll over from their parent protocol and want to continue study drug. * female subjects of childbearing potential must have a negative serum or urine pregnancy test within 3 days of the first dose of study drug and agree to use dual methods of contraception during the study and for 1 month following the last dose with study drug. post menopausal females (\>45 years old and without menses for \>1 year) and surgically sterilized females are exempt from this criterion. * male subjects must use an effective barrier method of contraception during the study and for 3 months following the last dose if sexually active with a female of childbearing potential. * willing and able to participate in all required evaluations and procedures in this study protocol including swallowing capsules without difficulty * ability to understand the purpose and risks of the study and provide signed and dated informed consent and authorization to use protected health information (in accordance with national and local patient privacy regulations). exclusion criteria: * a life-threatening illness, medical condition or organ system dysfunction which, in the investigator's opinion, could compromise the subject's safety, interfere with the absorption or metabolism of pci-32765 po, or put the study outcomes at undue risk * known history of human immunodeficiency virus (hiv) or active infection with hepatitis c virus (hcv) or hepatitis b virus (hbv) or any uncontrolled active systemic infection. * lactating or pregnant

Keywords: pci-32765 lymphoma, b-cell leukemia, lymphoid leukemia, b-cell bruton's tyrosine kinase
clinical study on intensive multi-acupuncture in the treatment of lumbar muscle strain.

Conditions: Lumbar Muscle Strain

Summary: acupuncture is widely used as a routine treatment for lumbar muscle strain. the aim of this randomized controlled trial is to evaluate the effectiveness of the intensive multi-acupuncture method. this trial will include 108 patients with lumbar muscle strain injury from two outpatient clinics. all participants will be randomized in a 1:1 ratio to the intensive multi-acupuncture method group and the normal needling group. outcomes will be assessed before the intervention, after one treatment, after five treatments, and at follow-up 2 weeks after the end of treatment. the primary outcome indicator will be the clinical efficacy evaluation criteria, and the secondary outcome indicators will be the pain visual analog scale (vas) score, the japanese orthopaedic association assessment treatment score (joa) score, the lumbar joint mobility measurement scale, and the modified ashworth grading scale. this study will provide evidence as to whether the intensive multi-acupuncture method is safe and effective.


Eligibility criteria:
inclusion criteria: 1.meet the above chinese and western medicine diagnostic criteria; 2.18 years old ≤ age ≤ 70 years old, gender is not limited; 3.the duration of the disease is more than 3 months, no other treatment has been received in the last month, and the vas score is ≥4 at the time of participating in the treatment; 4.voluntarily cooperate with the examination and treatment, and sign the informed consent form. exclusion criteria: 1. those with severe cardiac, hepatic and renal insufficiency and those with bleeding tendency; 2. previous history of lumbar spine surgery, spinal cauda equina tumor, lumbar spondylolisthesis, lumbar spinal stenosis, scoliosis deformity, tumors and other diseases caused by low back pain; 3. women who are in the period of pregnancy or breastfeeding should not perform acupuncture treatment; 4. those who have needle-sickness, blood-sickness and so on; 5. those who have cognitive impairment and cannot complete the relevant scale assessment independently or under the guidance of the investigator.
telespirometry in amyotrophic lateral sclerosis (als)

Conditions: Amyotrophic Lateral Sclerosis

Summary: the investigators seek to validate slow vital capacity (svc) measurement in seated and supine positions using conventional and portable spirometry.

svc is obtained with in-clinic conventional spirometry, in-clinic portable spirometry, and in-home portable spirometry with respiratory therapist-supervised remote pulmonary function testing every two weeks in a six month prospective study of participants with a diagnosis of amyotrophic lateral sclerosis. svc decline over time, seated and supine, will be tracked with assessments for treatment changes.

Eligibility criteria:
inclusion criteria: 1. diagnosis of als as clinically possible, clinically probable, laboratory-supported probable and clinically definite als 2. 18 years old to 100 years old, english-speaking als subjects, male and female exclusion criteria: 1. use of non-invasive ventilation more than 16 hours daily 2. non-english speaker 3. psychosis or severe mental illness 4. use of high-dose sedating psychotropic medications determined to potentially interfere with task performance 5. infection control issues and specific pulmonary, cardiac, vascular contraindications as listed in the standardization of spirometry 2019 update (graham 2019)

Keywords: pulmonary function test amyotrophic lateral sclerosis slow vital capacity
identification for the treatment of complex arrhythmias

Conditions: Arrhythmias

Summary: the primary purpose of this trial is to demonstrate that the utilization of cartofinder™ 4d local activation time (lat) algorithm may help identify and improve the outcome for the treatment of complex arrhythmias.


Eligibility criteria:
inclusion criteria: 1. age ≥ 18 years. 2. signed the patient informed consent form (icf) 3. scheduled to undergo a clinically-indicated catheter ablation procedure for treatment of * persistent atrial fibrillation (defined as continuous atrial fibrillation that is sustained beyond seven consecutive days). * drug-resistant atrial fibrillation. (failed 1 or more class i or iii antiarrhythmic drugs) and demonstrating persistent af (requiring drugs or electrical shock to terminate) * persistent af despite prior conventional ablation. 4. previous procedure permitted but limited to single pulmonary vein isolation (pvi). 5. in af at the time of the pre-cartofinder map (spontaneous or induced) 6. able and willing to comply with all pre-, post-, and follow-up testing and requirements. exclusion criteria: 1. paroxysmal atrial fibrillation 2. continuous af \> 12 months (1-year) (longstanding persistent af) 3. cardioversion refractory (the inability to restore sinus rhythm for 30 secs or longer following electrical cardioversion. if a patient does not have documented evidence of being successfully cardioverted (normal sinus rhythm (nsr) \> 30 secs), the patient must be cardioverted prior to the ablation procedure. failure to cardiovert based on the above criteria is considered a screen failure. 4. a complex arrhythmia secondary to a reversible or non-cardiac cause. for example: a complex arrhythmia secondary to electrolyte imbalance or thyroid disease. 5. left atrial size \>55 mm (echocardiography, parasternal long axis view). 6. significant congenital anomaly or medical problem that in the opinion of the investigator would preclude enrollment in this study. 7. structural atrial disease such as a prior history of atriotomy from prior atrial surgery, presence of an atrial septal defect, and/or presence of an atrial septal closure patch. 8. history of or current blood clotting or bleeding abnormalities, contraindication to systemic anticoagulation (i.e., heparin, warfarin, dabigatran, or a direct thrombin inhibitor), significant pulmonary disease, cardiac surgeries, unstable angina, uncontrolled heart failure, acute illness or systemic infection, or any other disease or malfunction that would preclude treatment in the opinion of the investigator. 9. enrollment in an experimental study evaluating another device or drug under investigation. 10. prosthetic valve 11. presence of intramural thrombus, tumor or other abnormality / condition that precludes vascular access, catheter introduction or manipulation. 12. women of child bearing potential whom are pregnant, lactating, or planning to become pregnant during the course of the trial. 13. presenting contra-indications for the devices used in the study, as indicated in the respective instructions for use.